

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Barouch et al.	Confirmation No.:	4894
Serial No.:	10/580,105	Art Unit:	1644
371(c) Date:	May 2, 2007	Examiner:	M. Dibrino
Customer No.:	21559		
Title:	ADJUVANTS OF IMMUNE RESPONSE		

REPLY TO RESTRICTION REQUIREMENT

In reply to the Restriction Requirement that was mailed in connection with the above-captioned case on April 1, 2010, Applicants elect the follow species:

- a. env as both immunogen and antigen;
- b. MIP-1 $\alpha$ ;
- c. HIV as a condition to be treated; and
- d. GM-CSF as an additional adjuvant.

Claims 1, 5, 7-9, 12, 15-17, 19-28, and 40-43 read on the elected species. This election is made with/without traverse.

To the extent that the Office is willing to examine additional immunogens or additional adjuvants, Applicants respectfully request examination of the Gag, Pol, and Nef immunogens or the Flt3L adjuvant.